Research Grade Motavizumab

Summary

Catalog No.	DVV02803
Alternative Names	MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3
Clone ID	Motavizumab
Host species	Humanized
Species reactivity	HRSV-A
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4.
Concentration	1 mg/ml
Purity	>95% as determined by SDS-PAGE.
Clonality	Monoclonal
Isotype	IgG1, kappa
Applications	Research Grade Biosimilar
Target	F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Purification	Protein A/G purified from cell culture supernatant.
Endotoxin level	Please contact with the lab for this information.
Expression system	Mammalian Cells
Accession	P03420

Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description

Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .

Data Image



SDS-PAGE

SDS PAGE for Motavizumab



Bioactivity

Detects F/Fusion glycoprotein F0 in indirect ELISAs.